# Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)

> **NCT07253129** · — · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 88 (estimated)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Allogenic stem cell transplant (ASCT)

## Key facts

- **NCT ID:** NCT07253129
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2029-05-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253129, "Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07253129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*